A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
BeOne Medicines
National Institutes of Health Clinical Center (CC)
Beijing Biotech
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Radboud University Medical Center
Sellas Life Sciences Group
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Amgen
Hoffmann-La Roche
Allogene Therapeutics
Lyell Immunopharma, Inc.
ModernaTX, Inc.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
A2 Biotherapeutics Inc.
Celgene
Immatics US, Inc.
Regeneron Pharmaceuticals
Dana-Farber Cancer Institute
AstraZeneca
ModernaTX, Inc.
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Haihe Biopharma Co., Ltd.
Amgen
University of Kansas Medical Center
DualityBio Inc.
Fondazione Italiana Linfomi - ETS
Australian & New Zealand Children's Haematology/Oncology Group
GlaxoSmithKline
Blueprint Medicines Corporation
Hoffmann-La Roche
Kura Oncology, Inc.
Karyopharm Therapeutics Inc
Genmab
Sun Yat-sen University
Icahn School of Medicine at Mount Sinai
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
MediLink Therapeutics (Suzhou) Co., Ltd.
Seqker Biosciences, Inc.
Novelwise Pharmaceutical Corporation
Universitair Ziekenhuis Brussel
Regeneron Pharmaceuticals
Immatics Biotechnologies GmbH
University of California, San Diego
Incyte Corporation